Novo Nordisk has filed a lawsuit against telehealth company Hims & Hers, alleging infringement of US Patent 8,129,343 related to its semaglutide products. The company claims that Hims & Hers is marketing unapproved, compounded versions of its FDA-approved medicines for weight loss and diabetes, including knock-off versions of Wegovy® and Ozempic®. Novo Nordisk is seeking a permanent ban on the sale of these unapproved drugs and is pursuing damages, emphasizing concerns about patient safety and the use of inauthentic active pharmaceutical ingredients in the compounded products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001163726-en) on February 09, 2026, and is solely responsible for the information contained therein.